Note: The author of this site is not engaged in rendering professional advice or services to the individual reader. The ideas, procedures, and suggestions contained within this work are not intended as a substitute for consulting with your physician. All matters regarding your health require medical supervision. I shall not be liable or responsible for any loss or damage allegedly arising from any information or suggestions within this blog. You, as a reader of this website, are totally and completely responsible for your own health and healthcare.
In the second study the primary aim was the efficacy evaluation on the long-acting beta 2 -agonist component of Fostair NEXThaler. In this study bronchodilation at the onset and up to 12 hrs after single doses administration was measured by serial spirometric evaluations of FEV 1 (FEV 1 AUC over at least 80% of formoterol duration of action). Compared with placebo, Fostair NEXThaler, one inhalation and four inhalations of both actives significantly improved the FEV 1 AUC 0-12 . Both doses of Fostair NEXThaler inhalation powder were non-inferior to the corresponding dose of the pressurised inhalation solution formulation. A statistically significant dose-response was found with both formulations between the low and high dose.